These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21793717)

  • 1. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study.
    Lemarie E; Vecellio L; Hureaux J; Prunier C; Valat C; Grimbert D; Boidron-Celle M; Giraudeau B; le Pape A; Pichon E; Diot P; el Houfia A; Gagnadoux F
    J Aerosol Med Pulm Drug Deliv; 2011 Dec; 24(6):261-70. PubMed ID: 21793717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
    Abratt RP; Bezwoda WR; Falkson G; Goedhals L; Hacking D; Rugg TA
    J Clin Oncol; 1994 Aug; 12(8):1535-40. PubMed ID: 8040664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
    Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
    Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
    Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
    J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
    Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
    Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
    Wang LR; Liu J; Huang MZ; Xu N
    J Zhejiang Univ Sci B; 2007 May; 8(5):307-13. PubMed ID: 17542057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine: safety profile unaffected by starting dose.
    Martin C; Pollera CF
    Int J Clin Pharmacol Res; 1996; 16(1):9-18. PubMed ID: 9001925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
    Asai G; Fukuoka M
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):884-9. PubMed ID: 10396314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Strojan P
    J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
    Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
    J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
    Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
    Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
    Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
    Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer.
    Blackstock AW; Ho C; Butler J; Fletcher-Steede J; Case LD; Hinson W; Miller AA
    J Thorac Oncol; 2006 Jun; 1(5):434-40. PubMed ID: 17409896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.